Clinical trial · Interventional
Randomized Trial of Exercise on Lower Extremity Edema After Lymphadenectomy in Gynecologic Cancer
Randomized Trial of Pelvic and Lower Extremity Exercise in Patients Who Underwent Pelvic Lymphadenectomy With Lower Extremity Edema-related Symptoms
NCT01849224CI-TRIAL-00011364unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary outcome is the change in lower extremity edema-related symptoms. Secondary outcomes include the compliance rate of management guidelines for lower extremity edema, the performance rate for pelvic and lower extremity exercise.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gynecologic Cancer | Malignant Female Reproductive System Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pelvic and lower extremity exercise | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Pelvic and lower extremity exercise
- description
- Experimental arm will be educated the guidelines for prevention and early detection of lower extremity edema. Additionally, pelvic and lower extremity exercise will be educated and participants will continue exercise for 1 year at home.
- interventionNames
- Other: Pelvic and lower extremity exercise
- type
- NO_INTERVENTION
- label
- Control
- description
- Control group will be educated the guidelines for prevention and early detection of lower extremity edema
Primary outcomes (1)
- measure
- Change in lower extremity edema-related symptoms after pelvic and lower extremities exercise
- timeFrame
- 1 year after randomization
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * More than 18 years of age * Patients who underwent pelvic lymphadenectomy * Patients with suspicious pelvic cancer who finished active treatments such as chemotherapy, radiotherapy or surgery. The interval between the time of randomization and the end of the treatment should be more than 2 weeks. * The patient is able to understand the study and is willing to give written informed consent to the study * patient with edema-related symptoms such as leg heaviness, distension, tightness, pain, limited movement, or weakness etc. Exclusion Criteria: * Severe systemic diseases causing peripheral edema, including renal disease * Severe or uncontrolled cardiopulmonary disease, including implantable device such as a pacemaker * Acute superficial or deep vein thrombosis * Previous major surgery for lower extremities, including metallic surgical implant * Local infection in the lower extremities * Auto-immunological disorders or vasculitis * Use of systemic corticosteroids * Pregnant or currently breastfeeding * Alcohol or drug abuse * Uncontrolled diabetes
References
Publications (0)
Data not yet available
No reference posted for this study.